These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25322440)

  • 81. Controlled multi-arm platform design using predictive probability.
    Hobbs BP; Chen N; Lee JJ
    Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Sequential urn designs with elimination for comparing K > or =3 treatments.
    Coad DS; Ivanova A
    Stat Med; 2005 Jul; 24(13):1995-2009. PubMed ID: 15803441
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Semiparametric transformation models for panel count data with correlated observation and follow-up times.
    Li N; Zhao H; Sun J
    Stat Med; 2013 Jul; 32(17):3039-54. PubMed ID: 23297190
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes.
    Wason JM; Mander AP
    J Biopharm Stat; 2012; 22(4):836-52. PubMed ID: 22651118
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data.
    Shinohara K; Tanaka S; Imai H; Noma H; Maruo K; Cipriani A; Yamawaki S; Furukawa TA
    Evid Based Ment Health; 2019 Feb; 22(1):10-16. PubMed ID: 30665989
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Response-adaptive designs for continuous treatment responses in phase III clinical trials: A review.
    Biswas A; Bhattacharya R
    Stat Methods Med Res; 2016 Feb; 25(1):81-100. PubMed ID: 22425657
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A nested group sequential framework for regional evaluation in global drug development program.
    Wang W; Jiang Z; Qiu J; Xia J; Guo X
    J Biopharm Stat; 2017; 27(6):945-962. PubMed ID: 28323515
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Bayesian optimal response-adaptive design for binary responses using stopping rule.
    Komaki F; Biswas A
    Stat Methods Med Res; 2018 Mar; 27(3):891-904. PubMed ID: 27142983
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Sequential conditional probability ratio tests for normalized test statistic on information time.
    Xiong X; Tan M; Boyett J
    Biometrics; 2003 Sep; 59(3):624-31. PubMed ID: 14601763
    [TBL] [Abstract][Full Text] [Related]  

  • 93. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
    Kelly PJ; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dose finding with the sequential parallel comparison design.
    Wang JJ; Ivanova A
    J Biopharm Stat; 2014; 24(5):1091-101. PubMed ID: 24919070
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Single-arm phase II trial design under parametric cure models.
    Wu J
    Pharm Stat; 2015; 14(3):226-32. PubMed ID: 25846141
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interim monitoring in sequential multiple assignment randomized trials.
    Wu L; Wang J; Wahed AS
    Biometrics; 2023 Mar; 79(1):368-380. PubMed ID: 34571583
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.
    Bowden J; Mander A
    Pharm Stat; 2014; 13(3):163-72. PubMed ID: 24692348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.